Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Esperite    ESP   NL0009272137


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

CRYO SAVE GROUP : -Save Group N.V. : Announcement determination of stock dividend ratio

share with twitter share with LinkedIn share with facebook
share via e-mail
06/01/2012 | 12:10pm EDT

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announced today the determination of the stock dividend ratio related to the dividend for the year ended 31 December 2011 as approved by the Annual General Meeting of Shareholders on 16 May 2012.

The average price during the period 18 May 2012 up to and including 1 June 2012 was € 3.47. The number of dividend rights giving entitlement to one Cryo-Save Group N.V. share has on 1 June 2012 (after market) been set at 43 (or at the choice of the banks or stockbroker where a shareholder holds its shares 4,300 dividend rights gives entitlement to 100 shares). Payment of stock dividend is only made in whole shares; fractions of shares are settled in cash.

The Group announces that shareholders wish to receive a distribution in shares for 29% of the total dividend.

The cash distribution will be payable and the shares will be delivered as per 14 June 2012.

In this context a total of approximately 63,000 new shares will be issued, charged to the share premium reserve, representing a Euro equivalent of approximately €216,000. The cash dividend will amount to €526,000 before withholding 15% dividend withholding tax.

Paying Agent: Kempen & Co N.V.



Cryo-Save Group + 31 (0) 575 548 998
Arnoud van Tulder, Chief Executive Officer
SPJ Financiële Communicatie (The Netherlands) +31 (0)20 647 8181
Kees Jongsma/Leon Melens

Daniel Stewart & Company plc (UK) + 44 (0) 20 7776 6550
Martin Lampshire
College Hill (UK) + 44 (0) 20 7457 2020
Rozi Morris/ Adrian Duffield

Free footage is available on www.videobankonline.com:

About Cryo-Save (www.cryo-save.com/group:

Cryo-Save, the leading international family stem cell bank, stores more than 200,000 samples from umbilical cord blood, cord tissue and adipose tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in over 40 countries on 3 continents, with ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India, South Africa and France (validation in progress).

Please click here for full press release in PDF:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Cryo-Save Group N.V. via Thomson Reuters ONE

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ESPERITE
10/01Global Stem Cell (Cord Blood Banking) Market Value Expected To Grow To $10.79..
10/01ESPERITE N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidia..
09/19ESPERITE : CryoSave has maintained without compromise the highquality processing..
09/19ESPERITE : CryoSave has maintained without compromise the high-quality processin..
08/27ESPERITE : And myrisoph capital conclude a strategic agreement on cryo-save's fa..
07/04ESPERITE : ESP) announces termination of audit engagement in relation to 2018 an..
07/04ESPERITE N.V. : announces termination of audit engagement in relation to 2018 an..
06/30ESPERITE : N.V. (ESP) publishes its half-year report. Revenues, results and cons..
06/28ESPERITE N.V. : Update to the market on the publication of the Annual Report 201..
06/26ESPERITE : ESP) announces termination of negotiations regarding proposed sale of..
More news
Duration : Period :
Esperite Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ESPERITE
Short TermMid-TermLong Term
Frédéric A. Amar Chief Executive Officer & Executive Director
Gert-Jan van der Marel Chairman
Ronald Hans Wilmar Lorijn Independent Non-Executive Director
Vincent M. F. Borgeot Independent Non-Executive Director
Aurelie Martin Manager-Genetics Product
Sector and Competitors